Literature DB >> 21428892

Exploring old drugs for the treatment of hematological malignancies.

F Gan1, B Cao, D Wu, Z Chen, T Hou, X Mao.   

Abstract

Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21428892     DOI: 10.2174/092986711795328427

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  2 in total

1.  Identification of levothyroxine antichagasic activity through computer-aided drug repurposing.

Authors:  Carolina L Bellera; Darío E Balcazar; Lucas Alberca; Carlos A Labriola; Alan Talevi; Carolina Carrillo
Journal:  ScientificWorldJournal       Date:  2014-01-30

2.  A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.

Authors:  Juan Tang; Jingyu Zhu; Yang Yu; Zubin Zhang; Guodong Chen; Xiumin Zhou; Chunhua Qiao; Tingjun Hou; Xinliang Mao
Journal:  Oncotarget       Date:  2014-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.